AB Science S.A. (0Q77.L) LSE
0.93
+0.01999997(+2.20%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
0.93
+0.01999997(+2.20%)
Currency In EUR
Sector
Healthcare
Industry
Drug Manufacturers Specialty Generic
Employees
40
First IPO Date
October 19, 2012
| Name | Title | Pay | Year Born |
| Alain Moussy | Co-Founder, Chairman, President, Chief Executive Officer, MD & Scientific Director | 599,000 | 1964 |
| Denis Gicquel | Executive Vice-President | 42,000 | N/A |
| Albert Ahn | President of USA Operations | 0 | N/A |
| Alexis BERNARD | Head of Veterinary Sales | 0 | N/A |
| Christian FASSOTTE | Global Chief Medical Officer | 0 | N/A |
| Harshad KULKARNI | Head of Statistics | 0 | N/A |
| Laurent Guy | Chief Financial Officer | 0 | N/A |
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.